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Abstract
Background: Whether electroacupuncture is effective for patients with polycystic ovary syndrome is still
inconclusive. Therefore, this study aims to evaluate the add-on effects of electroacupuncture to conventional
drugs for the treatment of polycystic ovary syndrome.
Methods/design: This study is a two-center, open-labeled, randomized, controlled trial. A total of 116 eligible
patients with polycystic ovary syndrome will be randomly allocated in a 1:1 ratio to the electroacupuncture
plus clomiphene citrate group or to the clomiphene citrate group. Participants in the electroacupuncture plus
clomiphene citrate group will receive electroacupuncture treatment in addition to clomiphene citrate capsules, whereas
participants in the clomiphene citrate group will be prescribed clomiphene citrate capsules only. Electroacupuncture
treatment will be performed from the fifth day of menstruation or withdrawal bleeding until the next menstruation, in
three sessions per week for three menstrual cycles. The primary outcome is the ovulation rate. The secondary outcomes
include the dominant follicle rate, mean number of dominant follicles, endometrial thickness, time point of ovulation,
follicular size before ovulation, luteinizing hormone, estradiol level, and pregnancy rate. The measuring points
for outcomes will be baseline and the completion of treatment. Any adverse events occurring during the trial
process will be recorded. In addition, a quality-monitoring group independent from the research team will be
set up to control the quality of the trial.
Discussion: The design and methodological rigor of this trial will allow for the collection of valuable data to
evaluate the effectiveness of electroacupuncture for treating polycystic ovary syndrome. Therefore, this trial
will contribute reliable evidence for use in clinical decision-making in acupuncture therapy of polycystic ovary
syndrome as well as to future research in acupuncture for polycystic ovary syndrome.
Trial registration: Chinese Clinical Trial Registry, ChiCTR-IOR-15007358, registered on 26 October 2015
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Background
Polycystic ovary syndrome (PCOS), resulting from an
imbalance of hormones, is a common disease in women.
Its clinical manifestations vary, but include reproductive
symptoms (hirsutism [1], infertility [2], pregnancy impli-
cations, and neonatal complications [3]) and metabolic
complications (obesity [4], impaired glucose tolerance,
metabolic syndrome [5], and type 2 diabetes mellitus
[6]). Usually, many psychological comorbidities accom-
pany PCOS, including depression, anxiety, moodiness,
panic attacks, body dissatisfaction, eating disorders, and
a lower health-related quality of life [7, 8]. As one of the
common causes of anovulatory infertility, PCOS ac-
counts for a significant proportion (40 %) of all women
who receive infertility treatment [2]. More than 116
million (3.42 %) women worldwide are affected by PCOS
[9]. Using the Rotterdam criteria, the prevalence has
been as high as 17.8 ± 2.8 % [10].
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Currently, first-line conventional therapy for infertile
women with PCOS is the oral administration of anties-
trogen agents (for example, clomiphene citrate). Never-
theless, from a clinical point of view, the current
management of PCOS with these drugs is not always
satisfactory and produces some obvious side effects.
After taking clomiphene citrate, metformin, or both,
41 %, 76.3 %, and 31.6 % of women, respectively, still
failed to ovulate [11]. The live-birth rate for these
patients was only 22.5 % after taking clomiphene citrate,
7.2 % after taking metformin, and 26.8 % after taking
both clomiphene citrate and metformin. Among preg-
nancies, clomiphene citrate caused multiple pregnancies
in 6.0 % of the cases. Other side effects include gastro-
intestinal symptoms, hot flashes, and symptoms associ-
ated with ovarian enlargement and ovulation [12].
Whereas first-line conventional therapy is not satisfac-
tory, acupuncture, as a nonpharmacological therapy, is
gaining popularity. Findings from previous clinical trials
suggest acupuncture may induce ovulation [13]; improve
menstrual frequency [14]; and improve depression, anx-
iety, and health-related quality of life [15] in PCOS
patients. Some of the mechanisms underlying acupunc-
ture as a treatment for PCOS have been identified. Acu-
puncture is able to decrease abnormally high levels of
circulating luteinizing hormone (LH), which affect the
LH/follicle-stimulating hormone (FSH) ratio [14, 16],
and high levels of testosterone [17]. Additionally, the
low associated adverse-events rate, a low risk of multiple
pregnancies, and the low cost of acupuncture have been
noted [18]. However, the methodological quality of these
clinical trials varies, resulting in inconclusive statements
on the effectiveness of acupuncture for PCOS. In this
case, we designed this two-center, open-labeled, random-
ized controlled trial (RCT) to evaluate the add-on effects
of electroacupuncture to conventional drugs on ovula-
tion and some sex hormones in women with PCOS.
Methods/design
Overview of the study design
We designed an open-labeled RCT. The interventions
will be performed under ideal circumstances. Therefore,
this trial will be carried out in academic settings: the
First Affiliated Hospital of Chengdu University of
Traditional Chinese Medicine and the Third Affiliated
Hospital of Chengdu University of Traditional Chinese
Medicine. The flow is shown in Fig. 1.
Before inclusion, participants will be screened in the
aforementioned research centers. If the participants
meet the inclusion criteria and agree to participate, they
will be asked to sign the informed consent form and,
then, will be randomized into the electroacupuncture
plus clomiphene citrate group (EA group) or the clomi-
phene citrate group (CC group).
After randomization, the participants will go through a
total treatment period of three menstrual cycles. Out-
come measurements will be assessed by assessors,
blinded to the group assignment, at baseline and the end
of treatment. Adverse events will be recorded for the as-
sessment of safety. In addition, a quality monitoring
board will be set up to control the quality of the proto-
col implementation.
The study protocol has been reviewed and approved
by local institutional review boards and ethics commit-
tees. It follows the principles of the CONSORT and
STRICTA statements as well as the Declaration of
Helsinki (Sixth revision, 2008). Informed consent will be
obtained from all participants.
Ethics approval
All trial procedures place the participant’s benefit as the
highest priority. The present study protocol has already
been ethically approved by the Sichuan Regional Ethics
Review Committee on Traditional Chinese Medicine
with the ethical approval identifier 2015KL-009.
Participants
We plan to recruit patients with PCOS diagnosed on the
basis of Revised 2003 Consensus on Diagnostic Criteria
and Long-Term Health Risks Related to Polycystic Ovary
Syndrome established by The Rotterdam ESHRE/ASRM-
Sponsored PCOS Consensus Workshop Group [19].
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Fig. 1 Flow chart of the trial
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According to these criteria, women with two out of
three of the following items can be diagnosed as having
PCOS: (1) oligoovulation or anovulation, (2) clinical
and/or biochemical signs of hyperandrogenism, and (3)
polycystic ovaries and exclusion of other etiologies (con-
genital adrenal hyperplasia, androgen-secreting tumors,
Cushing’s syndrome). Further assessment of eligibility is
based on the inclusion and exclusion criterion as
follows.
Inclusion criteria
1. Female, age 20 to 40 years
2. Diagnosed as having PCOS
3. Sign the inform consent
Exclusion criteria
1. Allergic constitution or allergic to various kinds of
medicine
2. Hyperandrogenism due to other reasons, including
hyperprolactinemia, thyroid disease, congenital
adrenal hyperplasia, Cushing’s syndrome, etc.
3. Pathological endometrial changes, such as uterine
malformation, hysteromyoma, etc., diagnosed by B
ultrasound
4. Genital tract malformation, gonadal dysgenesis,
fallopian tube block, etc.
5. Severe heart, liver, or renal dysfunction or
hematological, respiratory, cardiovascular,
psychiatric, or other metabolic diseases
6. Within 6 weeks post-abortion
7. Use of hormonal or other medication including
Chinese herbal prescriptions in the past 3 months
8. Participation in other clinical trials at the same time
Randomization
In this trial, participants will be randomly assigned to
either the EA group or the CC group in a 1:1 ratio
using a table of random numbers. The random num-
bers are generated using SAS statistical software pack-
age (Version 9.1, SAS Institute Inc.).
Blinding
This is an open-labeled trial; therefore, neither the
patients nor the clinical practitioners will be blinded for
the entire process. However, in order to eliminate poten-
tial bias, other researchers, including data collectors and
statisticians, will be blinded.
Interventions
Participants in the EA group will receive electroacu-
puncture treatment in addition to the oral administra-
tion of clomiphene citrate, whereas participants in the
CC group will receive clomiphene citrate only. Treat-
ment in both group will last three menstrual cycles. The
intervention in this trial involves a rigorous acupuncture
schedule. To ensure the compliance of acupuncturists to
the schedule, we ask them to take pretrial training and
an entrance exam for this trial. All included acupunctur-
ists will have at least 2 years of practical experience in
clinical acupuncture.
Clomiphene citrate therapy
On the fifth day of menstruation, all participants, except
for those with amenorrhea, will receive a pharmaco-
logical treatment regimen of 50 mg clomiphene citrate,
taken once each day for 5 continuous days. Patients with
amenorrhea will receive the same pharmacological treat-
ment regimen after withdrawal bleeding has been in-
duced by taking progestin. In cases of no ovulation, an
additional 50 mg will be added to the dose in the next
menstrual cycle. The maximum dose will not exceed
150 mg. The therapy will last for three menstrual cycles.
Electroacupuncture
In order to increase the reproducibility and internal val-
idity of the trial, electroacupuncture treatment will be
applied to PCOS patients. As the stimulation of electroa-
cupuncture can be more quantifiable relative to manual
acupuncture, its employment may reduce the risk of bias
somewhat. Sanyinjiao (SP 6), Guanyuan (BL 26) Zhongji
(CV 3), and Zigong (EX-CA 1) have been chosen for the
formula of compulsory acupoints. Additionally, sets of
three arbitrary points will be alternately selected accord-
ing to the phase of the menstrual cycle: Taichong (LR 3)
and Taixi (KI 3) will be needled after menstruation;
Mingmen (GV 4) and Xuehai (SP 10), during the ovula-
tory period; and Xuehai (SP 10) and Geshu (BL 17),
before the next menstruation.
Each acupoint will be needled using a filiform needle
(25–50 mm in length and 0.25 mm in diameter) to
achieve a Deqi sensation (refers to a sensation of numb-
ness, distension, or electrical tingling at the needling site
and might radiate along the corresponding meridian).
Then, an auxiliary needle (13 mm in length and
0.18 mm in diameter) will be inserted, 2 mm lateral to
the first needle, to a depth of 2 mm without achieving
Deqi. Electrical stimulation will be applied at every acu-
point, with one electrode connected to the filiform nee-
dle and the other to the auxiliary needle. This method
circumscribes the electrical stimulation nearby, rather
than going across the human body surface to cause per-
formance bias. Electrical stimulation will last for 30 min
in each acupuncture session. Electroacupuncture treat-
ment will be performed three times per week from the
fifth day of menstruation or withdrawal bleeding until
before the next menstruation for three menstrual cycles.
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Outcome measurements
Primary outcome
The primary outcome will be the ovulation rate.
Secondary outcomes
The secondary outcomes will include the dominant
follicle rate, mean number of dominant follicles, endo-
metrial thickness, time point of ovulation, follicular size
before ovulation, luteinizing hormone (LH) level, estra-
diol (E2) level, and pregnancy rate.
Time points of outcome measurement
Outcomes will be assessed at two time points: baseline
and the completion of the treatment. Furthermore,
patients will be given some regular tests at baseline, in-
cluding routine blood tests, liver function test, and kidney
function test. The overview of the outcome measurement
at the different time points is shown in Table 1.
Assessment of adverse events
According to previous RCTs, acupuncture may cause
several types of adverse events, including subcutaneous
hematoma, bleeding, skin bruising, and needle site pain.
Among these adverse events, subcutaneous hematoma
and bleeding were the most common [20]. Acupuncture-
related adverse events, including bleeding, hematoma,
fainting, serious pain, local infection, etc., will be carefully
recorded in the case report forms.
Sample size calculation
A previous study indicated that 59 % of women with
PCOS ovulated after receiving clomiphene citrate [11].
In this trial, the ovulation rate is expected to be 75 % in
the EA group and 55 % in the CC group. Considering a
significant level of 0.05 and a power of 0.80, 50 partici-
pants in each group are required, as calculated by t test
in G*Power (Version 3, Institute for Experimental Psych-
ology, Heinrich-Heine-University, Germany). At least 58
participants per group and 116 total participants will be
recruited to allow for a 15 % dropout rate.
Statistical analysis
A statistician blinded to the whole trial process will per-
form the statistical analyses using the SAS statistical
software package (Version 9.1, SAS Institute Inc.) in the
Computer Integrated Manufacturing System. For the
evaluation of a curative effect in this trial, the full ana-
lysis set (FAS) will be used. The FAS is determined ac-
cording to an intention-to-treat (ITT) population; all
randomized patients who receive at least one treatment
session will be included in the analysis set. The per-
protocol analysis set (PPS) is defined as the patients who
complete the study and do not have major protocol vio-
lations. Demographic data and other basic indicators will
be analyzed to test the balance of the two groups at
baseline. The main indicators and global indicators will
be analyzed within the FAS and PPS. The results will be
described with mean, standard deviation, median, P25
(percentile 25), P75 (percentile 75), maximum, and mini-
mum values of the differences between the treatment
period and the baseline period. Between-group differ-
ences will be tested using repeated measure analyses of
the variance. The accepted level of significance for all
analyses was P < 0.05. Considering the influences of
other factors on the effectiveness, such as age, duration
of disease, etc., these factors will be considered as covar-
iants for the covariance analysis or logistic regression
analysis when comparisons are made between the
groups. Missing data will be replaced according to the
principle of multiple imputations.
Quality monitoring
To control the trial’s quality, an independent quality-
monitoring group will be established. The project leader
will be in charge of the whole quality monitoring,
whereas supervisors will be in charge of the quality
monitoring in each center. The whole process will be
Table 1 Trial process chart
Time point Baseline Post-treatment
Diagnosis
Inclusion confirmed ✓
Informed consent signed ✓




Current treatment ✓ ✓
Outcome assessment
B ultrasound ✓ ✓
Follicle-stimulating hormone ✓ ✓
Luteinizing hormone ✓ ✓
Testosterone ✓ ✓
Estradiol ✓ ✓
Blood HCG ✓ ✓
Regular tests
Routine blood tests ✓
Liver function test ✓
Kidney function test ✓
Data collection and statistical analysis
Adverse event ✓
Causes of dropout ✓
Safety analysis ✓
Compliance analysis ✓
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supervised. All data will be verified to ensure they are
recorded and reported accurately, authentically, com-
pletely, and consistently with the original data.
Discussion
The present trial is a comparative study of the effective-
ness of electroacupuncture on ovulation and some
related sex hormones in patients with PCOS.
Due to the weakness of the methodological design, the
overall quality of clinical trials concerning the effective-
ness of acupuncture treatment for infertility in women
with PCOS is relatively low [18]. Although an ongoing
multicenter RCT is underway, more RCTs that are prop-
erly designed are needed before drawing conclusions
concerning the use of acupuncture in the management
of PCOS [21]. Therefore, this trial is designed as an RCT
to evaluate the add-on effects of electroacupuncture to
conventional drugs on PCOS in terms of promoting
ovulation and regulating related hormones. This study
has several strengths.
On one hand, this trial is designed as an RCT. Due to
its ability to reduce spurious causality and bias, the RCT
is the most reliable scientific evidence in the hierarchy
of evidence and can influence healthcare policy and
practice. The RCT, the gold standard in clinical trials, is
often used to test the efficacy or effectiveness of various
types of medical interventions and may provide informa-
tion about adverse effects. Therefore, this rigorously
designed RCT, which will evaluate the effectiveness of
electroacupuncture on PCOS in terms of promoting
ovulation and regulating related hormones, will be able
to provide some reliable evidence regarding the use of
acupuncture for PCOS.
On the other hand, the therapeutic principle of treat-
ment based on the phase of the menstrual cycle will be
followed in this trial. In traditional Chinese Medicine,
treatment based on syndrome differentiation is an im-
portant therapeutic principle. In gynecological diseases,
treatment based on the phase of the menstrual cycle is
another important principle and can enhance thera-
peutic effects. Therefore, this principle will be followed
in our study. Sanyinjiao (SP 6), Zigong (EX-CA 1),
Guanyuan (BL 26), and Zhongji (CV 3) have been
chosen as the compulsory acupoints. These four acu-
points are the ones most frequently used to treat PCOS,
according to a text-mining analysis [22]. Sanyinjiao (SP
6) and Zigong (EX-CA 1) are important acupoints for
the treatment of gynecological diseases in acupuncture
practice. Guanyuan (BL 26) can reinforce kidney and
warm Yang. Zhongji (CV 3) is located in the Conception
Vessel and is used to regulate the Chong Vessel and
Conception Vessel. In addition, according to a previous
study [23], three sets of arbitrary points will be alter-
nately selected according to the phase of the menstrual
cycle, with each group consisting of two acupoints. After
menstruation, Taichong (LR 3) and Taixi (KI 3) will be
punctured to regulate qi and nourish the liver and kid-
neys. During the ovulatory period, Mingmen (GV 4) and
Xuehai (SP 10) will be punctured to tonify qi and regu-
late the blood to promote ovulation. Before the next
menstruation, Xuehai (SP 10) and Geshu (BL 17) will be
punctured to regulate the blood.
This rigorously designed trial will allow for the collec-
tion of valuable and reliable data to evaluate the effect-
iveness of a specific acupuncture protocol for treating
PCOS. This study will contribute to the clinical evidence
regarding the effectiveness of electroacupuncture for
women with PCOS.
Trial status
The trial had not yet begun at the time of manuscript
submission.
Abbreviations
PCOS: polycystic ovary syndrome; EA: electroacupuncture; CC: clomiphene
citrate; LH: luteinizing hormone; E2: estradiol; FSH: follicle-stimulating
hormone; RCT: randomized controlled trial; CONSORT: Consolidated
Standards of Reporting Trials; STRICTA: Standards for Reporting Interventions
in Controlled Trials of Acupuncture; ESHRE: European Society of Human
Reproduction and Embryology; ASRM: American Society for Reproductive
Medicine; SAS: Statistical Analysis System; FAS: full analysis set; ITT: intention-
to-treat; PPS: per-protocol analysis set; P25: percentile 25; P75: percentile 75.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JC and SWF contributed equally to the manuscript. JC conceived the study,
participated in its design, and drafted the manuscript. SWF participated in
the design and drafted the manuscript. JZZ, XW, MXY, HZT, and HYF
participated in the design and helped to draft the manuscript. JY and FRL
conceived the study, participated in its design, and helped to draft the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
This trial was financially supported by funds from the Science and
Technology Department of Sichuan Province (grant number 2015SZ0096).
Author details
1Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan,
China. 2Maternal and Child Health Hospital of Sichuan Province, Chengdu,
Sichuan, China. 3Sichuan Orthopedic Hospital, Chengdu, Sichuan, China.
Received: 10 December 2015 Accepted: 15 April 2016
References
1. Escobar-Morreale HF, Carmina E, Dewailly D, Gambineri A, Kelestimur F,
Moghetti P, et al. Epidemiology, diagnosis and management of hirsutism:
a consensus statement by the Androgen Excess and Polycystic Ovary
Syndrome Society. Hum Reprod Update. 2012;18(2):146–70.
2. Joham AE, Teede HJ, Ranasinha S, Zoungas S, Boyle J. Prevalence of
infertility and use of fertility treatment in women with polycystic ovary
syndrome: data from a large community-based cohort study. J Womens
Health. 2015;24(4):299–307.
3. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS.
A meta-analysis of pregnancy outcomes in women with polycystic ovary
syndrome. Hum Reprod Update. 2006;12(6):673–83.
4. Moran L, Teede H. Metabolic features of the reproductive phenotypes of
polycystic ovary syndrome. Hum Reprod Update. 2009;15(4):477–88.
Chen et al. Trials  (2016) 17:256 Page 5 of 6
5. Marcondes JA, Hayashida SA, Barcellos CR, Rocha MP, Maciel GA, Baracat EC.
Metabolic syndrome in women with polycystic ovary syndrome:
prevalence, characteristics and predictors. Arq Bras Endocrinol Metabol.
2007;51(6):972–9.
6. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors
of risk for type 2 diabetes mellitus and impaired glucose tolerance in
polycystic ovary syndrome: a prospective, controlled study in 254 affected
women. J Clin Endocrinol Metab. 1999;84(1):165–9.
7. Deeks AA, Gibson-Helm ME, Teede HJ. Anxiety and depression in polycystic
ovary syndrome: a comprehensive investigation. Fertil Steril. 2010;93(7):
2421–3.
8. Himelein MJ, Thatcher SS. Polycystic ovary syndrome and mental health:
A review. Obstet Gynecol Surv. 2006;61(11):723–32.
9. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years
lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries
1990-2010: a systematic analysis for the Global Burden of Disease Study
2010. Lancet. 2012;380(9859):2163–96.
10. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The
prevalence of polycystic ovary syndrome in a community sample assessed
under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544–51.
11. Zain MM, Jamaluddin R, Ibrahim A, Norman RJ. Comparison of clomiphene
citrate, metformin, or the combination of both for first-line ovulation
induction, achievement of pregnancy, and live birth in Asian women with
polycystic ovary syndrome: a randomized controlled trial. Fertil Steril. 2009;
91(2):514–21.
12. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, et al.
Clomiphene, metformin, or both for infertility in the polycystic ovary
syndrome. N Engl J Med. 2007;356(6):551–66.
13. Johansson J, Redman L, Veldhuis PP, Sazonova A, Labrie F, Holm G, et al.
Acupuncture for ovulation induction in polycystic ovary syndrome: a
randomized controlled trial. Am J Physiol Endocrinol Metab. 2013;304(9):
E934–43.
14. Zheng YH, Wang XH, Lai MH, Yao H, Liu H, Ma HX. Effectiveness of
abdominal acupuncture for patients with obesity-type polycystic ovary
syndrome: a randomized controlled trial. J Altern Complement Med. 2013;
19(9):740–5.
15. Stener-Victorin E, Holm G, Janson PO, Gustafson D, Waern M.
Acupuncture and physical exercise for affective symptoms and
health-related quality of life in polycystic ovary syndrome: secondary
analysis from a randomized controlled trial. BMC Complement Altern
Med. 2013;13:131.
16. Maliqueo M, Benrick A, Alvi A, Johansson J, Sun M, Labrie F, et al. Circulating
gonadotropins and ovarian adiponectin system are modulated by
acupuncture independently of sex steroid or beta-adrenergic action in a
female hyperandrogenic rat model of polycystic ovary syndrome. Mol Cell
Endocrinol. 2015;412:159–69.
17. Jedel E, Labrie F, Oden A, Holm G, Nilsson L, Janson PO, et al. Impact
of electro-acupuncture and physical exercise on hyperandrogenism and
oligo/amenorrhea in women with polycystic ovary syndrome: a
randomized controlled trial. Am J Physiol Endocrinol Metab. 2011;300(1):
E37–45.
18. Lim DC, Chen W, Cheng LN, Xue CC, Wong FW, O’Sullivan AJ, et al.
Acupuncture for polycystic ovarian syndrome. Cochrane Database Syst Rev.
2011;8:CD007689.
19. Rotterdam EA-SPCWG. Revised 2003 consensus on diagnostic criteria and
long-term health risks related to polycystic ovary syndrome. Fertil Steril.
2004;81(1):19–25.
20. Zhao L, Zhang FW, Li Y, Wu X, Zheng H, Cheng LH, et al. Adverse events
associated with acupuncture: three multicentre randomized controlled trials
of 1968 cases in China. Trials. 2011;12:87.
21. Kuang H, Li Y, Wu X, Hou L, Wu T, Liu J, et al. Acupuncture and clomiphene
citrate for live birth in polycystic ovary syndrome: study design of a
randomized controlled trial. eCAM. 2013;2013:527303.
22. Pu J. Acupoints analysis by data mining in polycystic ovary syndrome and
its related symptom. Heilongjiang: Heilongjiang University Of Chinese
Medicine; 2012.
23. Wu K. Random controlled prospective study of the treatment for PCOS by
acupuncture and Chinese medicine combined. Guangdong: Guangzhou
University of Chinese Medicine; 2011.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Chen et al. Trials  (2016) 17:256 Page 6 of 6
